Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Glenn Seaborg and John Livingood at the University of California, Berkeley

2

Pfizer

420

Eli Lilly

237

Merck

216

GlaxoSmithKline

193

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1951

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

hyperthyroidism

2

thyroid carcinomas

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

DAILYMED

2

DRUG BANK

2

EPA CompTox

2

FDA UNII

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DIAGNOSTIC RADIOPHARMACEUTICALS

2

THERAPEUTIC RADIOPHARMACEUTICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

THYROID

2

OTHER THERAPEUTIC RADIOPHARMACEUTICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Various thyroid diagnostic radiopharmaceuticals

2

Iodine (131I) compounds

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

IODIDE ION I-131

4GC1FOQ22U

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

hyperthyroidism

thyroid carcinomas

Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take ...

up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.

SODIUM IODIDE I-131

29VCO8ACHH

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

hyperthyroidism

thyroid carcinomas

Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take ...

up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1